IP Library Granted Patent US 10,588,914
Granted Patent B2
US 10,588,914 · App. 16/242,562 · Granted Mar 17, 2020

Topical formulations comprising a steroid

Inventors: Udhumansha Ubaidulla (Namakkal, IN); Sateesh Kandavilli (Plainsboro, NJ); Ajay Sunil Vairale (Hyderabad, IN); Jeffrey A. Wayne (Markham, CA); Vijendra Nalamothu (Basking Ridge, NJ); Mistry Meghal (Ahmedabad, IN); Refika Isil Pakunlu (Highland Park, NJ)
Assignee: ENCORE DERMATOLOGY, INC.
A61K31/573A61K9/0014A61K9/107A61K9/7015A61K31/56A61K31/575A61K31/58A61K47/10A61K47/14A61K47/22A61K47/26A61K47/32A61K47/36A61K47/38A61K47/44B05B1/02B05B1/30B05B11/3045B05B15/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,914
App. No.
16/242,562
Granted
Mar 17, 2020
Kind
B2
Abstract

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Claims (20)

1. A topical pharmaceutical composition comprising:

an active agent consisting of clobetasol propionate wherein the amount of the active agent consisting of clobetasol propionate is about 0.01% to about 1% of the total weight of the composition;

at least one emulsifying agent wherein the amount of the at least one emulsifying agent is about 0.25% to about 45% of the total weight of the composition;

a skin penetration enhancer wherein the amount of the skin penetration enhancer is about 3% to about 10% of the total weight of the composition;

at least one emollient wherein the amount of the at least one emollient is about 0.01% to about 45% of the total weight of the composition;

an antioxidant wherein the amount of antioxidant is about 0.01% to about 20%, of the total weight of the composition;

at least one preservative wherein the amount of the at least one preservative is about 0.25% to about 25%, of the total weight of the composition;

a water immiscible substance;

at least one alcohol;

and water;

wherein the composition is propylene glycol free, non-foaming, and propellant-free.

2. The topical pharmaceutical composition of claim 1 , wherein the emulsifying agent is glyceryl stearate, a polyethylene glycol stearate, or any combination thereof.

3. The topical pharmaceutical composition of claim 1 , wherein the skin penetration enhancer is diethylene glycol monoethyl ether.

4. The topical pharmaceutical composition of claim 1 , wherein the water immiscible substance is wax.

5. The topical pharmaceutical composition of claim 1 , further comprising a polymer and wherein the polymer is a polysiloxane.

6. The topical pharmaceutical composition of claim 1 , wherein the emollient is isopropyl myrisate.

7. The topical pharmaceutical composition of claim 1 , wherein the at least one alcohol is cetyl alcohol stearyl alcohol or a combination thereof.

8. The topical pharmaceutical composition of claim 1 , wherein the antioxidant is butylated hydroxytoluene.

9. The topical pharmaceutical composition of claim 1 , wherein the at least one preservative is methylparaben, propylparaben, or any combination thereof.

10. A method of treating plaque psoriasis in a subject comprising: topically administering an effective amount of a composition as in any one of claims 1 - 9 to the subject.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: ENCORE DERMATOLOGY, INC.
To: PRIMUS PHARMACEUTICALS, INC.
Reel/Frame 055576/0523 →
SECURITY INTEREST Recorded Nov 11, 2020
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: PENNRX VENTURES, LLC
Reel/Frame 054337/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 049062/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: UBAIDULLA, UDHUMANSHA; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; VAIRALE, AJAY SUNIL; KANDAVILLI, SATEESH; WAYNE, JEFFREY A.; PAKUNLU, REFIKA ISIL
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 049061/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 049061/0794 →
SECURITY INTEREST Recorded Apr 22, 2019
From: ENCORE DERMATOLOGY, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 048958/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 048941/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2019
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 048081/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2019
From: UBAIDULLA, UDHUMANSHA; KANDAVILLI, SATEESH; VAIRALE, AJAY SUNIL; WAYNE, JEFFREY A.; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; PAKUNLU, REFIKA ISIL
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 047932/0575 →